Adaptive Biotechnologies Corporation (ADPT) has a consensus analyst rating of Buy, based on 17 analysts covering the stock. Of those, 11 recommend buying, 4 recommend holding, and 2 recommend selling.
The analyst consensus price target for ADPT is $21.25, representing a +46.2% upside from the current price of $14.53. Price targets range from a low of $21.00 to a high of $22.00.
